Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
NCT00143234
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Clinical diagnosis of both elevated blood pressure and low density lipoprotein cholesterol levels, requiring medication
- Patients with blood pressure adequately maintained at goal with or without medication
- Patients currently treated with both amlodipine and atorvastatin or not at blood
pressure or lipid level while taking the highest dose of amlodipine or atorvastatin,
respectively
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Beijing, Beijing
- Guangzhou, Guangdong
- Guangzhou, Guangdong
- Guangzhou, Guangdong
- Nanjing, Jiangsu
- Shen Yang, Liaoning
- Shanghai, Shanghai
- Hangzhou, Zhejiang
- Beijing,
- Beijing,
- Beijing,
- Shanghai,
- Shanghai,
- Shanghai,
- Tianjin,
- Salzburg,
- St. Poelten,
- Vienna,
- Wels,
- Bierbeek,
- Braine-L'Alleud,
- Brugge,
- De Pinte,
- Gozée,
- Seraing,
- Wemmel,
- Wilrijk,
- Zedelgem,
- Helsinki,
- Kuopio,
- Kuopio,
- Oulu,
- Oulu,
- Tampere,
- Turku,
- Turku,
- Vantaa,
- Heraklion, Crete
- Athens,
- Ioannina,
- Larissa,
- Melissia,
- Pireaus,
- Rio, Patra,
- Thessaloniki,
- Thessaloniki,
- Budapest,
- Budapest,
- Budapest,
- Debrecen,
- Kecskemét,
- Miskolc,
- Mosonmagyaróvár,
- Pécs,
- Szekszárd,
- Gorey, Wexford
- New Ross, Wexford
- Vimercate, (mi)
- Somma Lombardo, (va)
- San Sisto, PG
- Mestre, VE
- Asti,
- Bologna,
- Bologna,
- Bologna,
- Bolzano,
- Brescia,
- Catania,
- Catania,
- Chieti,
- Ferrara,
- Firenze,
- Foggia,
- Genova,
- Grosseto,
- Napoli,
- Novara,
- Palermo,
- Palermo,
- Perugia,
- Potenza,
- Prato,
- Roma,
- Salerno,
- Sassari,
- Siena,
- Torino,
- Venezia,
- Guilhufe - Pnf, Penafiel
- Matosinhos, Sra. da Hora
- Coimbra,
- Faro,
- Leiria,
- Lisboa,
- Lisboa,
- Lisbon,
- Porto,
- Porto,
- S. Martinho Do Bispo,
- Viana Do Castelo,
- Izola,
- Ljubljana,
- Maribor,
- San Sebastian, Guipuzcoa
- Reus, Tarragona
- Barcelona,
- Barcelona,
- Madrid,
- Madrid,
- Baden, AG
- Bern, BE
- Basel, BS
- St. Gallen, SG
- Münsterlingen, TG
- Lugano, TI
- Lausanne, VD
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- St. Leonards, New South Wales
- Southport, Queensland
- Woolloongabba, Queensland
- Heidelberg, Victoria
- Melbourne, Victoria
- Prahran, Victoria
- Fremantle, Western Australia
- Belo Horizonte, MG
- Belo Horizonte, MG
- Belo Horizonte, MG
- Recife, PE
- Botucatu, SP
- Campinas, SP
- Ribeirao Preto, SP
- Sao Paulo, SP
- São Paulo, SP
- Santiago, Región Metropolitana
- Santiago, RM
- Guatemala,
- Pokfulam Road,
- Sai ying Pun,
- Hyderabad, Andhra Pradesh
- Hyderabad, Andhra Pradesh
- Bangalore, Karnataka
- Mumbai, Maharashtra
- Pune, Maharashtra
- Mumbai, Nagpada Junction
- New Delhi,
- New Delhi,
- New Delhi,
- Jakarta,
- Jakarta,
- Surabaya,
- Jerusalem,
- Jerusalem,
- Rehovot,
- Tel Aviv,
- Tel Hashomer,
- Amman,
- Amman,
- Seo-gu, Busan
- Jung-gu, Daegu
- Dong-gu, Kwangji
- Anyang-city, Kyungki-do
- Guri-City, Kyungki-do
- Gangnam-gu, Seoul
- Yongdeungpo-gu, Seoul
- Seoul,
- Seoul,
- Seoul,
- Sasat,
- Beirut,
- Kubang Kerian, Kelantan
- Seremban, Negeri Sembilan
- Kuching, Sarawak
- Kuala Lumpur,
- Kuala Lumpur,
- Mexico, D.F
- Aguascalientes,
- Metepec,
- Mexico,
- Puebla,
- San Luis Potosi,
- Casablanca,
- Peshawar, N.w.f.p.
- Faisalabad, Punjab
- Islamabad, Punjab
- Lahore, Punjab
- Lima,
- San Juan, Metro Manila
- Phippine General Hospital, Taft Avenue, Manila City
- Filinvest, Alabang,
- Manila,
- Quezon City,
- Quezon City,
- Al-Khobar,
- Riyadh,
- Riyadh,
- Singapore,
- Singapore,
- Worcester, Cape Province
- Arcadia, Pretoria, Gauteng
- Midrand, Johannesburg, Gauteng
- Sunnyside, Pretoria, Gauteng
- Chatsworth, Natal
- Cape Town,
- Cape Town,
- Cape Town,
- Gauteng,
- Kwa-Zulu Natal,
- Niao-Sung Hsiang, Kaohsiung
- Guei-Shan Shiang, Tau-Yuan Shian
- Changhua City,
- Taipei,
- Taipei,
- Taipei,
- Khet Rajathevee, Bangkok
- Bangkok,
- Chiang Mai,
- Tunis,
- Cebeci, Ankara
- Sihhiye, Ankara
- Haydarpasa, Istanbul
- Alsancak, Izmir
- Talas, Kayseri
- Adana,
- Antalya,
- Diyarbakir,
- Istanbul,
- Abu Dhabi,
- Dubai,
- Sharjah,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels | |||
Official Title ICMJE | Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia | |||
Brief Summary | The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE | Drug: Amlodipine/atorvastatin single pill | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 1825 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | July 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 80 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Argentina, Australia, Brazil, Chile, Guatemala, Hong Kong, India, Indonesia, Israel, Jordan, Korea, Republic of, Kuwait, Lebanon, Malaysia, Mexico, Morocco, Pakistan, Peru, Philippines, Saudi Arabia, Singapore, South Africa, Taiwan, Thailand, Tunisia, Turkey, United Arab Emirates | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00143234 | |||
Other Study ID Numbers ICMJE | A3841024 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2021 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |